Scholarlink

<p>Optimal selection of patients with locally advanced rectal cancer for watch and wait (WW) and optimal management during follow-up remain challenging. We employed a primary-tumor-informed whole genome sequencing (WGS) assay to detect circulating tumor DNA (ctDNA) and estimate tumor fraction (TF) before, during and after neoadjuvant therapy. ctDNA was detected in 95% of baseline samples, and TF was a significant baseline predictor of sustained clinical complete response (scCR). High TF during or after neoadjuvant therapy was associated with lower likelihood of scCR and higher risk of relapse. Very low TF during surveillance was detected in a large proportion of patients who did not experience a recurrence, suggesting the existence of persisting low amounts of ctDNA. WGS-based ctDNA assessment thus provides high sensitivity, which is crucial for treatment de-escalation, but additional research is needed to also ensure good specificity (the trial is registered in ClinicalTrials.gov with the identifier NCT02008656).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ultrasensitive ctDNA monitoring for organ preservation in patients with locally advanced rectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月11日

查看全文
  • Paolo Manca,
  • Chin-Tung Chen,
  • Farheen Shah,
  • Christina Lee,
  • Dylan Domenico,
  • Dana Omer,
  • Santiago Gonzalez,
  • Ino De Bruijn,
  • Samuel Ahuno,
  • Walid K. Chatila,
  • Madison Darmofal,
  • Iman Tavassoly,
  • Adam J. Widman,
  • Michael F. Berger,
  • Brian Loomis,
  • Elli Papaemmanuil,
  • Rona Yaeger,
  • Asaf Zviran,
  • Julio Garcia-Aguilar,
  • Francisco Sanchez-Vega

摘要

Optimal selection of patients with locally advanced rectal cancer for watch and wait (WW) and optimal management during follow-up remain challenging. We employed a primary-tumor-informed whole genome sequencing (WGS) assay to detect circulating tumor DNA (ctDNA) and estimate tumor fraction (TF) before, during and after neoadjuvant therapy. ctDNA was detected in 95% of baseline samples, and TF was a significant baseline predictor of sustained clinical complete response (scCR). High TF during or after neoadjuvant therapy was associated with lower likelihood of scCR and higher risk of relapse. Very low TF during surveillance was detected in a large proportion of patients who did not experience a recurrence, suggesting the existence of persisting low amounts of ctDNA. WGS-based ctDNA assessment thus provides high sensitivity, which is crucial for treatment de-escalation, but additional research is needed to also ensure good specificity (the trial is registered in ClinicalTrials.gov with the identifier NCT02008656).